Schultz SH, North SW, Shields CG. Schizophrenia: a review. Am Fam Physician. 2007;75(12):1821–9.

PubMed  Google Scholar 

Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–23.

Article  PubMed  CAS  Google Scholar 

Vita A, Gaebel W, Mucci A, et al. European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia. Eur Psychiatry. 2022;65(1): e57.

Article  PubMed  PubMed Central  Google Scholar 

Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin N Am. 2007;30(3):437–52.

Article  Google Scholar 

Brissos S, Veguilla MR, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kishimoto T, Hagi K, Kurokawa S, et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387–404.

Article  PubMed  Google Scholar 

Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs. 2004;18(2):113–32.

Article  PubMed  CAS  Google Scholar 

Janssen Pharmaceuticals. RISPERDAL® CONSTA® (risperidone) long-acting injection: US prescribing information. 2003. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021346_s31_s35_s38_s39lbl.pdf. Accessed 25 Nov 2024.

European Medicines Agency. OKEDI 75 mg and 100 mg powder and solvent for prolonged-release suspension for injection: EU summary of product characteristics. 2024. https://www.ema.europa.eu/en/documents/product-information/okedi-epar-product-information_en.pdf. Accessed 25 Nov 2024.

Laboratorios Farmacéuticos Rovi. RISVAN® (risperidone) for extended-release injectable suspension, for intramuscular use: US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214835s000lbl.pdf. Accessed 25 Nov 2024.

Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48(2):253-73.

Marder SR, Cannon TD. Schizophrenia. N Engl J Med. 2019;381(18):1753–61.

Article  PubMed  CAS  Google Scholar 

Li P, Snyder GL, Vanover KE. Dopamine targeting drugs for the treatment of schizophrenia: past, present and future. Curr Top Med Chem. 2016;16(29):3385–403.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Anta L, Mata E, Ochoa Díaz de Monasterioguren L. Newer formulations of risperidone: remarks about risperidone ISM®. CNS Drugs. 2020;34(10):1087–8.

Article  PubMed  Google Scholar 

Llaudó J, Anta L, Ayani I, et al. Phase I, open-label, randomized, parallel study to evaluate the pharmacokinetics, safety, and tolerability of one intramuscular injection of risperidone ISM at different dose strengths in patients with schizophrenia or schizoaffective disorder (PRISMA-1). Int Clin Psychopharmacol. 2016;31(6):323–31.

Article  PubMed  Google Scholar 

Alamo C. Risperidone ISM as a new option in the clinical management of schizophrenia: a narrative review. Adv Ther. 2022;39(11):4875–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Farre M, Martinez-Gonzalez PCJ. A clinical trial to evaluate the pharmacokinetics, safety and tolerability of single doses of risperidone with the novel long-acting injectable technology ISM® in healthy subjects [abstract no. O-04-005]. Eur Arch Psychiatry Clin Neurosci. 2011;261(Suppl 1):S57.

Google Scholar 

European Medicines Agency. Okedi (risperidone): assessment report. Procedure No. EMEA/H/C/005406/0000. 2022. https://www.ema.europa.eu/en/medicines/human/EPAR/okedi. Accessed 25 Nov 2024.

Laboratorios Farmacéuticos Rovi. Risperidone for extended-release injectable suspension (OKEDI®): product monograph. 2024. https://pdf.hres.ca/dpd_pm/00075022.PDF. Accessed 25 Nov 2024.

Carabias LA, Llaudó J, Ayani I, et al. A phase II study to evaluate the pharmacokinetics, safety, and tolerability of risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia. Int Clin Psychopharmacol. 2018;33(2):79–87.

Article  Google Scholar 

Walling DP, Hassman HA, Anta L, et al. The steady-state comparative bioavailability of intramuscular risperidone ISM and oral risperidone: an open-label, one-sequence study. Drug Des Devel Ther. 2021;15:4371–82.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Laveille C, Snoeck E, Ochoa Díaz de Monasterioguren L, et al. Development of a population pharmacokinetic model for the novel long-acting injectable antipsychotic risperidone ISM®. Br J Clin Pharmacol. 2024;90(9):2256–70.

Article  PubMed  CAS  Google Scholar 

Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44(6):195–235.

Article  PubMed  Google Scholar 

Data on file, Laboratorios Farmacéuticos Rovi. 2024.

Snoeck E, Luyckx N, Laveille C, et al. Pharmacokinetic/pharmacodynamic modeling and simulation of dopamine D2-receptor occupancy-time profiles comparing risperidone ISM versus daily oral risperidone [abstract no. P.0245 plus poster]. Neurosci Appl. 2023;2(Suppl 2):119–20.

Google Scholar 

Correll CU, Litman RE, Filts Y, et al. Efficacy and safety of once-monthly risperidone ISM® in schizophrenic patients with an acute exacerbation. NPJ Schizophr. 2020;6(1):1–9.

Article  PubMed  PubMed Central  Google Scholar 

Filts Y, Litman RE, Martinez J, et al. Long-term efficacy and safety of once-monthly risperidone ISM® in the treatment of schizophrenia: results from a 12-month open-label extension study. Schizophr Res. 2022;239:83–91.

Article  PubMed  CAS  Google Scholar 

Litman R, Naber D, Anta L, et al. Personal and social functioning and health-related quality of life in patients with schizophrenia treated with the long-acting injectable antipsychotic risperidone ISM. Neuropsychiatr Dis Treat. 2023;19:219–32.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Litman RE, Anta L, Filts Y, et al. Cardiovascular safety profile of the long-acting antipsychotic risperidone ISM in patients with schizophrenia treated in a phase 3 clinical trial [abstract no. P.0190]. Neurosci Appl. 2022;1(Suppl 2):90–1.

Google Scholar 

American Psychiatric Association. The American Psychiatric Association Practice Guideline for the treatment of patients with schizophrenia (3rd edition). 2021. https://doi.org/10.1176/appi.books.9780890424841.

Barnes TR, Drake R, Paton C, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2020;34(1):3–78.

Article  PubMed  Google Scholar 

Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78.

Article  PubMed  Google Scholar 

Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry. 2013;14(1):2–44.

Article  PubMed  Google Scholar 

Indivior Inc. PERSERIS (risperidone) for extended-release injectable suspension, for subcutaneous use: US prescribing information. 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210655s000lbl.pdf. Accessed 25 Nov 2024.

Teva Neuroscience. UZEDY® (risperidone) extended-release injectable suspension, for subcutaneous use: US prescribing information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213586s000lbl.pdf. Accessed 25 Nov 2024.

Janssen Pharmaceuticals. INVEGA® SUSTENNATM (paliperidone palmitate) extended-release injectable suspension: US prescribing information. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022264lbl.pdf. Accessed 25 Nov 2024.

Janssen Pharmaceuticals. INVEGA TRINZA™ (paliperidone palmitate) extended-release injectable suspension, for intramuscular use: US prescribing information. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207946s000lbl.pdf. Accessed 25 Nov 2024.

Janssen Pharmaceuticals. INVEGA HAFYERA™ (paliperidone palmitate) extended-release injectable suspension, for gluteal intramuscular use: US prescribing information. 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207946Orig1s010lbl.pdf. Accessed 25 Nov 2024.

Otsuka Pharmaceutical. ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension, for intramuscular use: US prescribing information. 2002. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202971s013lbl.pdf. Accessed 25 Nov 2024.

Sánchez P, Álamo C, Almendros M, et al. Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of paliperidone palmitate and aripiprazole monohydrate in 52-week studies. Ann Gen Psychiatry. 2023;22(1):1–10.

Article  Google Scholar 

Eli Lilly and Company. ZYPREXA RELPREVV (olanzapine) for extended-release injectable suspension: US prescribing information. 2009. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022173lbl.pdf. Accessed 25 Nov 2024.

Leucht S, Leucht C, Huhn M, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174(10):927–42.

Article  PubMed  Google Scholar 

Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;8(8):CD008016.

PubMed  Google Scholar